Effects of recombinant human growth hormone in catabolic adults with chronic renal failure

Growth Horm IGF Res. 2000 Apr:10 Suppl B:S31-7. doi: 10.1016/s1096-6374(00)80007-6.

Abstract

Growth hormone (GH) has been used for the treatment of catabolism in a few pilot studies and in two placebo-controlled studies of 6 months duration. Treatment with GH in doses of 2-4 IU/m2/day (0.67-1.33 mg/m2/day) resulted in clear anabolic effects and a significant change in body composition. Lean body mass increased by more than 3 kg within 6 months, whereas fat mass was decreased by the same amount, resulting in a constant total body weight. As there were no major side-effects, controlled long-term studies are justified.

Publication types

  • Review

MeSH terms

  • Adult
  • Body Mass Index
  • Body Weight / drug effects
  • Child
  • Clinical Trials as Topic
  • Glucose / metabolism
  • Hematopoiesis / drug effects
  • Human Growth Hormone / adverse effects
  • Human Growth Hormone / therapeutic use*
  • Humans
  • Kidney Failure, Chronic / drug therapy*
  • Nitrogen / metabolism
  • Pilot Projects
  • Placebos
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / therapeutic use*
  • Time Factors
  • Uremia / drug therapy

Substances

  • Placebos
  • Recombinant Proteins
  • Human Growth Hormone
  • Glucose
  • Nitrogen